Two Sigma Investments, LP Ngm Biopharmaceuticals Inc Transaction History

Two Sigma Investments, LP

$42.3 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.17 - $1.92 $541,377 - $888,414	-462,716 Reduced 94.33%	27,800 $44,000
Q4 2023 Feb 14, 2024	BUY	$0.6 - $1.31 $50,212 - $109,631	83,688 Added 20.57%	490,516 $421,000
Q3 2023 Nov 14, 2023	BUY	$1.05 - $3.37 $73,913 - $237,227	70,394 Added 20.92%	406,828 $435,000
Q2 2023 Aug 14, 2023	SELL	$2.44 - $4.53 $13,634 - $25,313	-5,588 Reduced 1.63%	336,434 $871,000
Q1 2023 May 15, 2023	BUY	$3.72 - $5.4 $233,735 - $339,292	62,832 Added 22.51%	342,022 $1.4 Million
Q4 2022 Feb 14, 2023	BUY	$3.41 - $12.93 $65,642 - $248,902	19,250 Added 7.41%	279,190 $1.4 Million
Q3 2022 Nov 14, 2022	BUY	$12.59 - $17.67 $1.15 Million - $1.61 Million	91,020 Added 53.88%	259,940 $3.4 Million
Q2 2022 Aug 15, 2022	BUY	$10.58 - $17.5 $229,818 - $380,135	21,722 Added 14.76%	168,920 $2.17 Million
Q1 2022 May 16, 2022	SELL	$13.81 - $18.6 $1.24 Million - $1.66 Million	-89,461 Reduced 37.8%	147,198 $2.25 Million
Q4 2021 Feb 14, 2022	BUY	$17.26 - $22.02 $489,131 - $624,024	28,339 Added 13.6%	236,659 $4.19 Million
Q3 2021 Nov 15, 2021	BUY	$20.15 - $26.19 $3.92 Million - $5.09 Million	194,420 Added 1398.71%	208,320 $4.38 Million
Q2 2021 Aug 16, 2021	SELL	$15.06 - $30.03 $816,959 - $1.63 Million	-54,247 Reduced 79.6%	13,900 $274,000
Q1 2021 May 17, 2021	BUY	$24.99 - $31.93 $1.7 Million - $2.18 Million	68,147 New	68,147 $1.98 Million
Q4 2020 Feb 16, 2021	SELL	$16.21 - $31.44 $803,075 - $1.56 Million	-49,542 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$15.59 - $19.97 $11,333 - $14,518	727 Added 1.49%	49,542 $788,000
Q2 2020 Aug 14, 2020	BUY	$11.97 - $23.47 $584,315 - $1.15 Million	48,815 New	48,815 $964,000

Others Institutions Holding NGM

# of Institutions

Shares Held

2.6M

Call Options Held

300

Put Options Held

View Full List

About NGM BIOPHARMACEUTICALS INC

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

More about NGM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.

Account